trial

Endocannabinoid Control of Microglia Activation as a New Therapeutic Target in the Treatment of Schizophrenia

NCTId NCT02932605
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 32 (actual)
Sponsored by UMC Utrecht
Primary completion 2020-01-31
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
32 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2017-11-03
Primary completion
2020-01-31
Eligibility
ALL · 16 Years · 40 Years

Interventions & indications

Drugs
Cannabidiol

Sponsors

UMC UtrechtLead Sponsor

Investigators

1
Matthijs Bossong, PhDPrincipal Investigator

Sites

1 total
Utrecht, Netherlands

Facts & assertions

4 sourced
Enrollment
32
Phase
NA
Primary Completion Date
2020-01-31
Status
COMPLETED
relationships
The graph out of here
drug
Cannabidiol
drug
lead_sponsor
UMC Utrecht
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Matthijs Bossong, PhD
person